CN101239076A - Blood plasma immunoregulation medicament capsule - Google Patents
Blood plasma immunoregulation medicament capsule Download PDFInfo
- Publication number
- CN101239076A CN101239076A CNA2008100546443A CN200810054644A CN101239076A CN 101239076 A CN101239076 A CN 101239076A CN A2008100546443 A CNA2008100546443 A CN A2008100546443A CN 200810054644 A CN200810054644 A CN 200810054644A CN 101239076 A CN101239076 A CN 101239076A
- Authority
- CN
- China
- Prior art keywords
- blood plasma
- medicine
- treatment
- capsule
- medicament capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a medicine capsule used for adjusting the plasma immunity. Each of the medicine dose unit contains 1 to 500mg plasma protein. The medicine takes a poultry egg as an adhesive agent. The fresh plasma is added into the poultry egg for full agitation, then dried and crushed into powder, and then the powder is added into the capsules. The medicine capsule can stimulate the immunity action, thus achieving the aim of health care and curing and preventing diseases. As the amount of the effective ingredients is small, no adverse drug reaction is occurred. Seen through the treatment to body aches, bronchial asthma, epilepsy, inflammatory aches, Meniere disease, etc., the capsule achieves good result.
Description
Technical field
The present invention relates to a kind of immunoregulation medicament, specifically relate to a kind of immunoregulation medicament made from blood plasma.Medicine of the present invention can be induced the exciting human immunoreation, to resist and to treat disease.
Background technology
Cytokine is the general designation by the protein matter of the biologically active of cell generation.By all means with cytokine as in the medicine donor, give full play to the biological action of cytokine, can be used for resisting and treating disease.With reasonable dosage, the reasonable compatibilities such as cytokine of trace,, can obtain following effect by inducing the immunoreation that excites intestinal tract Pai Shi set associated lymphoid tissue:
1, antiinflammatory action
Can suppress because of the inflammation due to bacterial infection, immunity, chemistry, radiation and the physical factor.Be similar to glucocorticoid, can stop inflammatory cell (lymphocyte, granulocyte, macrophage etc.) to move to inflammation part, the reaction that stops inflammatory mediator such as kassinin kinin class, histamine, slow reacting substance etc. to take place, stablize lysosome membrane, stop complement to participate in inflammatory reaction, increase the density of blood capillary, reduce its permeability, make and ooze out minimizing, tissue injury due to the inflammation-inhibiting.
2, anti-immunologic injury
Suppress super quick immunoreation by a plurality of links, make and organize T that autoantigen replys and B cell because of clonal anerge, clone do not activate, immunity is ignored and the immunosuppressant cell effect can not be carried out immunne response, recovery is to the immunologic tolerance of autoantigen, alleviate the symptom of anaphylaxis and autoimmune disease, and reach anti-immunologic injury effect.
3, improve interior environment, improve immune defence
Immune system cans be compared to human internal environment's cleaner, and the old and feeble foreign body, metabolism foreign body and the variation foreign body that produce in the body are engulfed, handle, discharged.By immunoreactive antiinflammatory and anti-immunologic injury effect; do not suppress the performance of normal immunologic function; but strengthened activity of immune cells; make it to concentrate strength on tackling invasion source of disease thing, the ability of engulfing, remove metabolism foreign body, old and feeble foreign body and variation foreign body strengthens, the spatter property and the stability of environment in improving; make gene expression normalization; created condition for impaired tissue repair, disease is able to Lock-out, the value high to being formed with of prophylaxis of tumours.
In addition, immunoreation is to other system, and especially the central nervous system peripheral nervous system of unifying also has wide influence.
Immunoreactive antiinflammatory and anti-immunologic injury effect can replace anti-inflammatory analgesic, antihistaminic and glucocorticoid medicine under many circumstances, obtain the curative effect that medicine has.When special necessity is used glucocorticoid, unite this immunoreation and also can reduce drug dose, shorten the course of treatment.
But because the cytokine class medicine is shorter in the intravital half-life of people, the injection that need give patient's high dose repeated multiple times can obtain certain curative effect, and this way tends to cause serious toxic and side effects.
The main component of blood plasma is water, protein, lower-molecular substance and oxygen etc., and plasma protein can be divided into albumin, globulin and Fibrinogen three classes.Modern medicine is used albumin, the blood plasma intravenous drip treatment shock that wound and burn etc. cause of losing blood always, and the cerebral due to cerebral edema and the cerebral lesion increases, and prevents edema and ascites that hypoproteinemia and hepatitis interstitialis chronica or nephropathy cause; With intramuscular injection or intravenous drip human to improve the resistance of human body to various bacteria, virus.
Contain A wide selection of colours and designs but the cytokine of trace in plasma protein, the cytokine molecular weight is less, mainly is present in the albumin.
Summary of the invention
The purpose of this invention is to provide a kind of blood plasma immunoregulation medicament capsule, this medicine can be induced challenge, demonstrates significant biological effect, is cured the disease, the purpose of diseases prevention, health care, and does not have any bad toxicity.
Based on the reasonable dosage of the cytokine of trace, by inducing the immunoreation that excites intestinal tract Pai Shi set associated lymphoid tissue, can obtain antiinflammatory action, anti-immunologic injury and improve interior environment, improve the mechanism of immune defence, the immunoregulation medicament that the blood plasma immunoregulation medicament capsule that use blood plasma is made and the cytokine of purification are made has the effect of different Qu Tonggong.Contain A wide selection of colours and designs in the blood plasma but the cytokine of trace, (15～30KD) albumen or glycoprotein are difficult to purification and extract (can extract low-molecular-weight albumen to improve the content of cytokine with separation and purification technique) for low-molecular-weight.And the cytokine that is contained in the blood plasma total protein of certain metering also can reach same significant biological effect.
Blood plasma immunoregulation medicament capsule of the present invention is made by blood plasma, contains blood plasma total protein 1～500mg in each pharmaceutical dosage unit.
The concrete preparation method of medicament capsule of the present invention be with fowl egg for depending on agent, blood plasma added in the fowl egg stir, dryly also be ground into powder, in incapsulating, contain the capsule of above-mentioned dose drug in making every.
Using method of the present invention is: each 1, every day 3～4 times, empty stomach is chewed or is swallowed.
Adopt the therapeutic modality of high dose repeated multiple times intramuscular injection or intravenous injection cytokine to compare with prior art, the effective ingredient dosage trace of blood plasma immunoregulation medicament capsule of the present invention, treat with oral administering mode, excite the intestinal mucosa lymphoid tissue by inducing, cause the immunoreation of whole body interlock type, can obtain antiinflammatory action, anti-immunologic injury effect and improve interior environment, improve the effect of immune defence.Be adapted to prevent disease, the rehabilitation of health of body and various acquired diseases, can be used for treating allergic disease, pain that inflammatory reaction causes, disease that chronic inflammatory disease causes, disease that nervous dysfunction causes such as mentally deranged, epilepsy etc., can also replace glucocorticoid, antihistaminic and anti-inflammatory analgesic etc. in some cases, have that acute disease is quick-acting, the therapeutic effect of chronic disease slow.
Because therefore the effective ingredient dosage trace of blood plasma immunoregulation medicament capsule of the present invention does not have any bad toxicity to human body.
The specific embodiment
Embodiment 1
Get the fresh plasma that contains 1000mg blood plasma total protein and add in the 800mL egg, stir, dry and be ground into egg powder, be filled in No. 2 capsules, make 1000 capsules, contain egg powder 190mg in every capsules, wherein blood plasma total protein 1mg.
Embodiment 2
Get the fresh plasma that contains 500g blood plasma total protein and add in the 800mL egg, stir, dry and be ground into egg powder, be filled in No. 2 capsules, make 1000 capsules, contain egg powder 190mg in every capsules, wherein blood plasma total protein 500mg.
Embodiment 3
Get the fresh plasma that contains 100g blood plasma total protein and add in the 800mL egg, stir, dry and be ground into egg powder, be filled in No. 2 capsules, make 1000 capsules, contain egg powder 190mg in every capsules, wherein blood plasma total protein 100mg.
Embodiment 4
Get the fresh plasma that contains 25g blood plasma total protein and add in the 800mL egg, stir, dry and be ground into egg powder, be filled in No. 2 capsules, make 1000 capsules, contain egg powder 190mg in every capsules, wherein blood plasma total protein 25mg.
Application examples 1
The analysis and summary of blood plasma immunoregulation medicament capsule treatment limb pain observation of curative effect
1, general clinical data
Since two thousand three, upper limb pain patients 24 examples that adopt blood plasma immunoregulation medicament capsule of the present invention treatment scapulohumeral periarthritis to cause, male's 10 examples wherein, women's 14 examples, 37～62 years old age; Rheumatism and patient with rheumatoid arthritis 18 examples, male's 11 examples wherein, women's 7 examples, 35～58 years old age; The lower limb that the fatigue of having a cold causes are stranded weak patient's 21 examples of pain, wherein male 9 examples, women 12 examples, 46～63 years old age; Adolescent growth pain patient 36 examples, male's 19 examples wherein, women's 17 examples, 5～14 years old age.
Above case all according to medical history, have a medical check-up and the X ray examination is got rid of bone lesion, chemical examination erythrocyte sedimentation rate etc. and made a definite diagnosis.
2, Therapeutic Method
Adopt blood plasma immunoregulation medicament capsule of the present invention, 1/time, can add 1 when pain is heavy every day 3 times, (medicine) being taken before meal or chew.
Scapulohumeral periarthritis group pain point partial closure 1～2 time, medicine prednisolone injection 125mg+2% lignocaine 5mL.
Adolescent growth is organized when pain is shown effect 1 of oral blood plasma immunoregulation medicament capsule of the present invention bitterly.
3, criterion of therapeutical effect
Produce effects: total pain relief or slight dull pain is only arranged; Effectively: pain is obviously alleviated, and pain can be stood; Invalid: pain is not alleviated fully.
4, therapeutic outcome
5, analysis and summary
Limb pain is because of the soft tissue injury of having a cold, chemical substance, mechanical irritation, antibacterial and detoxifying function thereof cause, produces as inflammatory mediators such as histamine, kassinin kinin class, slow reacting substance, prostaglandinss, and reactive pain causes inflammation.Blood plasma immunoregulation medicament capsule of the present invention obtains antiinflammatory action by inducing the immunoreation that excites intestinal tract Pai Shi set associated lymphoid tissue, can suppress because of the inflammation due to bacterial infection, immunity, chemistry, radiation and the physical factor.Be similar to glucocorticoid, can stop inflammatory cell (lymphocyte, granulocyte, macrophage etc.) to move to inflammation part, the reaction that stops inflammatory mediator such as kassinin kinin class, histamine, slow reacting substance etc. to take place, stablize lysosome membrane, stop complement to participate in inflammatory reaction, increase the density of blood capillary, reduce its permeability, make and ooze out minimizing, tissue injury due to the inflammation-inhibiting.Immunoreactive antiinflammatory and anti-immunologic injury effect can replace anti-inflammatory analgesic, antihistaminic and glucocorticoid medicine under many circumstances, obtain the curative effect that medicine has.
Application examples 2
Blood plasma immunoregulation medicament capsule treatment bronchial asthma 12 examples are observed and are summed up
1, general clinical data
Since two thousand three, adopt blood plasma immunoregulation medicament capsule treatment bronchial asthma 12 examples, each 6 example of men and women, 35～63 years old age, the course of disease 0.5～25 year.Wherein 2 routine male and 3 routine female ages are 53～71 years old, and the course of disease 15～25 years is with chronic bronchitis emphysema, pulmonary heart disease; 2 routine male's courses of disease 0.5～1 year, work asthma; 2 routine women's courses of disease 1.5～2 years, oiliness smog easily causes asthma; 2 routine male and 1 routine women's course of disease are 5～10 years in addition, are moderate asthma, ictal expiratory dyspnea with wheezing sound.
Above case is all through asthma treatment, aminophylline, the treatment of yarn butylamine alcohol effectively, according to medical history, have a medical check-up and X ray examination etc. is made a definite diagnosis.
2, Therapeutic Method
1), adopt blood plasma immunoregulation medicament capsule of the present invention, 1/time, every day 3 times, (medicine) being taken before meal is used.
2), continue former treatment, in, severe asthma gives aminophylline 6～10mg/kg, withdraw after symptom is clearly better; The control asthma attack with husky fourth ammonia alcohol spray with (or) glucocorticoid etc.
3, therapeutic outcome and tracing study
Adopt the blood plasma immunoregulation medicament capsule single therapy asthma attack phase of the present invention not have obvious curative effects.
The mild asthma treatment is after 2 months, and symptom obviously alleviates; Symptom disappears substantially after 3 months, and 2 routine work asthma and 2 routine oil smoke asthma were all treated 5 months altogether, observes 1～4 year, and 4 examples do not have the asthma of generation.
The moderate asthma patient treatment in 5～10 years of the 3 routine courses of disease after 3 months symptom be clearly better, all treated altogether 7 months, symptom disappears substantially, tracing study 1～3 year, 2 examples do not have the asthma of generation, and upper respiratory tract infection if take place in 1 example, asthma, cough promptly appear, through anti-infective therapy, and transference cure.
Occur together among the patient of chronic bronchitis, emphysema, pulmonary heart disease, 1 example treatment doing well,improving after 2 months, after cut out blood plasma immunoregulation medicament capsule treatment of the present invention; In addition 4 example treatments after 3 months symptom make moderate progress; It is obvious to treat after 5 months doing well,improving, all treats altogether 9～12 months, and symptoms of asthma disappears substantially, and chronic bronchitis cough, expectoration obviously alleviate, and emphysema, pulmonary heart disease symptom do not have positive effect.Tracing study 1.5～4 years, times of common cold obviously reduces, and quality of life improves, if upper respiratory tract infection takes place, then easily brings out asthma.The routine male sexual partner's breast of getting angry that takes place frequently wherein, the treatment back is observed pneumothorax was not taken place in 2.5 years.
4, analysis and summary
Bronchial asthma is the air flue chronic inflammation disease that is participated in by various kinds of cell (as eosinophilic granulocyte, mastocyte, T cell, neutrophilic granulocyte, airway epithelia cell etc.) and cellular component.Allergy, airway inflammation, airway reactivity increase and factor such as nerve and interaction thereof and pathogenesis of asthma in close relations.If the prolonged and repeated outbreak of asthma, can show as fibrosis, basement membrane thickened etc. under bronchial smooth muscle plumpness, the airway epithelia cell, cause airway remodeling and on every side lung tissue to the support effect disappearance of air flue.Outbreak is panted repeatedly, out of breath, uncomfortable in chest or cough is many with to contact allergen, cold air, physics, chemical irritation, viral upper respiratory tract infection, motion etc. relevant.
Adopt blood plasma immunoregulation medicament capsule of the present invention to excite the immunoreation of whole body interlock type, can reach antiinflammatory action, anti-immunologic injury effect and improve interior environment, improve immune defence by inducing.By the stage treatment, can make airway inflammation controlled, immunologic tolerance strengthens, and allergy, airway hyperreactivity tend to normal, and environment in improving from endogenous cause of ill makes asthma be difficult for generation for a long time.Because of there is physical factors in asthma, so the probability of recurrence exists, continue treatment and remain effectively, there is not drug resistance.
Application examples 3
Blood plasma immunoregulation medicament capsule treatment epilepsy observation analysis
1, general clinical data
Since 2003, adopt blood plasma immunoregulation medicament capsule of the present invention treatment epilepsy 8 examples, after wherein 2 routine male and 1 routine women are cerebral hemorrhage, be comprehensive epilepsy grand mal, 2 routine intravenous injection diazepam can not controlling symptoms; The comprehensive grand mal of 2 routine women's epilepsies has tangible family epilepsy medical history, and epilepsy medical history 1 year is surplus, and the discontinuity outbreak is 3～5 times, takes sodium valproate comparatively regularly more than half a year, the medication period epilepsy outbreak; 1 routine male be behind the cerebral trauma 2 years surplus, the epilepsy complex partial seizures, very rule is not taken phenytoin Sodium and is reached more than 1 year, medication period outbreak 3 times; 1 routine male is the epilepsy complex partial seizures from teenager's morbidity, irregular carbamazepine and the sodium valproate taken, outbreak in 1 year 2～5 times; 1 routine women is a febrile seizure, 3 years medical histories, outbreak in a year 2～3 times.
More than 8 routine cases all be according to medical history, epilepsy outbreak phase symptom, have a medical check-up and look into electroencephalogram or the brain CT examination is made a definite diagnosis.
2, Therapeutic Method
In epilepsy outbreak phase treatment, 1 of the thing of getting it filled is removed medicated powder in the entrance cavity.
3, therapeutic effect
Adopting blood plasma immunoregulation medicament capsule of the present invention to treat 8 examples, all is after medicine powder is sprinkled into the oral cavity during about 15 seconds, and epilepsy stops outbreak, and it is clear to realize, and the patient has slight dizziness, asthenia.Observed 1～5 year, and had only 2 examples after 1.5 years, to recur.
4, analysis and summary
Epilepsy is the of short duration brain function of a chronic repeated relapsing imbalance syndrome, with the excessive synchronous discharge of brain neuron and cause peripheral nerve unit synchronous movement to cause that repeatedly epilepsy outbreak is a feature.This altofrequency discharge is relevant with the depolarization shift that the neuron resting membrane electric potential prolongs.
Medicine of the present invention excites intestinal tract Pai Shi set lymphoid tissue to cause the immunoreation of whole body chain-type by inducing; can recover the polarization of neuron resting membrane electric potential rapidly; reparation causes epilepsy kitchen range normalization; the treatment epilepsy is fast rapid; only need about 15 seconds, and medication is convenient, medicated powder is sprinkled into the oral cavity gets final product; stable curative effect is difficult for recurrence.
Because of medicine of the present invention is not used for the treatment of the epilepsy stage of stable development as yet, whether treatment and preventive effect are arranged, still no matter fixed.
Application examples 4
The analysis and summary of blood plasma immunoregulation medicament capsule treatment inflammatory pain
1, general clinical data
Since 2002, Drug therapy acute appendicitis 31 examples of the present invention have been adopted, according to medical history, have a medical check-up and back surgical healing is made a definite diagnosis in blood routine examination etc.Treatment cholelithiasis, cholecystitis 20 examples are according to medical history, have a medical check-up and back surgical healing is made a definite diagnosis in ultrasound diagnosis etc.Headache 25 examples are sent out in the treatment spy of outbreak repeatedly, and are normal according to the headache clinical manifestation and the neurologic check of outbreak repeatedly, and inspections such as brain CT, MRI, and eliminating intracranial spaceoccupying lesion etc. is made a definite diagnosis.Treatment leg pain 21 examples that fatigue causes of having a cold are according to medical history, have a medical check-up and hematological examination is made a definite diagnosis.
2, Therapeutic Method
Acute appendicitis group and cholelithiasis, cholecystitis group are got 1 of medicine of the present invention in the pain stage of attack and are chewed and take.
Special send out the leg pain group that headache group and the fatigue of having a cold cause, 1/time, every day 3 times, (medicine) being taken before meal or chew adds 1 during the pain outbreak.
3, treatment standard
Produce effects: total pain relief, or mild pain is only arranged.Effectively: pain is obviously alleviated, and pain can be stood.Invalid: pain is not alleviated fully.
4, therapeutic effect
5, analysis and summary
Inflammatory pain and some chemical substances, mechanical irritation, antibacterial, toxin inflammation and inflammatory mediator such as histamine, kassinin kinin class, slow reacting substance, prostaglandins etc. stimulate relevant.
The present invention excites intestinal mucosa to follow Pai Shi set lymphoid tissue to cause the immunoreation of systemic immune system chain-type by inducing, and can reach antiphlogistic effect, can suppress because of the inflammation due to bacterial infection, immunity, chemistry, radiation and the physical factor.Its mechanism is similar to glucocorticoid, stops inflammatory mediator such as kassinin kinin class, histamine, slow reacting substance etc. to react, and tissue injury due to the inflammation-inhibiting is so there is good analgesic effect.
Application examples 5
Blood plasma immunoregulation medicament capsule treatment Meniere observation of curative effect is analyzed
1, general clinical data
Since 2002, blood plasma immunoregulation medicament capsule treatment Meniere 43 examples have been adopted, 15～72 years old age, male 23 examples, women 20 examples.Wherein the 18 routine courses of disease are 5～20 years, and once at how tame hospital therapy, often intravenous injection 654-2, lignocaine, sodium bicarbonate and take flunarizine etc. mostly can be fully recovered or take a turn for the better after treatment, but recurrence is frequent, with flunarizine treat hold time longer.5 routine patients are insensitive to treating, and are dizzy heavy, and tinnitus, deafness are lighter relatively, and headache often occurs together.The 25 routine courses of disease are 15 days～4 years in addition, intermittent attack, outbreak on the one is for several times, or a couple of days outbreak is once, and astasia sense in one to a few days is arranged after the outbreak.Mainly show that according to dizzy, tinnitus, deaf symptom, health check-up and electric hearing test sensorineural deafness, cranium brain CT examination no abnormality seen, X-ray sheet get rid of inspections such as cervical spondylosis and make a definite diagnosis.
2, Therapeutic Method
1/time, every day 3 times, can add 1 during paresthesia epilepsy.The course of disease is long, and the case of severe symptoms adds 1 of flunarizine, and every day 2 times is to sx.
3, criterion of therapeutical effect
Produce effects: long-term observation does not have dizzy generation, or only has slightly dizzy once in a while; Take a turn for the better: dizzy obvious alleviation, can stand, and the intermittent time is elongated; Invalid: dizzy not alleviation fully.
4, therapeutic outcome
5, analysis and summary
Adopt blood plasma immunoregulation medicament capsule treatment Meniere of the present invention that satisfied curative effect is arranged.Inflammatory mediator such as Meniere and histamine stimulates that acoustic nerve (cochlear nerve and vestibular nerve) causes intrinsic pressure increase in close relations, placenta immunoregulation medicament capsule can reach antiinflammatory action and improve the effect of interior environment, treat by the stage, the amelioration of inflammation reaction, the medium that diminishes inflammation stimulates, and the intrinsic pressure recovery of acoustic nerve (cochlear nerve and vestibular nerve) is normal, so curative effect is preferably arranged, and the recovery from illness back is continual and steady, is difficult for repeatedly.
Claims (2)
1, blood plasma immunoregulation medicament capsule is made by blood plasma, contains blood plasma total protein 1～500mg in each pharmaceutical dosage unit.
2, the preparation method of the described blood plasma immunoregulation medicament capsule of claim 1 is characterized in that with fowl egg for depending on agent, blood plasma is added in the fowl egg stir, and dryly also is ground into powder, in incapsulating, contains the capsule of above-mentioned dose drug in making every.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100546443A CN101239076A (en) | 2008-03-17 | 2008-03-17 | Blood plasma immunoregulation medicament capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100546443A CN101239076A (en) | 2008-03-17 | 2008-03-17 | Blood plasma immunoregulation medicament capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101239076A true CN101239076A (en) | 2008-08-13 |
Family
ID=39931088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100546443A Pending CN101239076A (en) | 2008-03-17 | 2008-03-17 | Blood plasma immunoregulation medicament capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101239076A (en) |
-
2008
- 2008-03-17 CN CNA2008100546443A patent/CN101239076A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kucukoner et al. | Complementary and alternative medicine usage in cancer patients in southeast of Turkey | |
| US10335538B2 (en) | System and treatment method to increase circulation and pluripotency of stem and progenitor cells within a patient | |
| US20150140012A1 (en) | Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis | |
| WO1994001099A1 (en) | Pharmaceutical composition having anti-alcohol, radioprotecting and anti-choleraic activity and stimulating energy metabolism, stomach mucous membrane acid-generation and secretion functions | |
| JP2016069495A (en) | Indoxyl sulfate production inhibitor | |
| CN107427493A (en) | Cebranopadol for the pain of the subject that treats liver function damage and/or impaired renal function | |
| WO2017146230A1 (en) | Test method | |
| JP3916563B2 (en) | Treatment method including administration of substance P | |
| CN101239076A (en) | Blood plasma immunoregulation medicament capsule | |
| CN1380071A (en) | Chinese medicine for curing psychosis and epilepsy | |
| NL2025295B1 (en) | Use of phenol in treatment of microbially induced dyspnoea | |
| Perera et al. | Evaluation of the effect and efficacy of selected herbal formula from ola leaves manuscript in the management of migraine | |
| Petermann | A holistic view of chronic disease with special consideration of adaptation syndrome and disturbing focus in controlled acupuncture | |
| Sudesh et al. | Effect of Matra Basti and Katibasti in the Management of Lumbar Disc Disease | |
| Patil et al. | Role of Ayurveda in the management of Post-traumatic chronic inflammatory synovitis of knee joint-A Case Report | |
| EP3763380A1 (en) | Method for treating encephalopathy | |
| RU2256460C2 (en) | Method for treating inspecific bronchopneumonia in calves | |
| RU2383350C1 (en) | Preparation and method for cleansing intestine, gallbladder and bile ducts | |
| Priya et al. | Acupressure on Bio Physiological Parameters among Patients Receiving Chemotherapy | |
| KR20200013627A (en) | Drowsiness driving factor, sleep apnea, and snoring machine | |
| CN108126048A (en) | Asthma medicament and preparation method thereof | |
| RU2188630C1 (en) | Means for treating and preventing narcomania | |
| Kim et al. | Medbulletins | |
| Webster et al. | LONG-TERM HYPERBARIC OXYGEN THERAPY FOR MULTIPLE SCLEROSIS PATIENTS | |
| LAM | NEUROPROSTHETIC EXOSKELETONS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080813 |